| Field | Specification |
|---|---|
| Mfr No | |
| Alternative Names | tumor necrosis factor receptor superfamily member 17, B-Cell Maturation Antigen, TNFRSF17, CD28, T-cell receptor zeta, 4-1BB, CD137 |
| Product Type | |
| Shipping | |
| Species | |
| Storage |
Scientific Background
The development of CAR-T cells is a complex process that requires I) screening and sequencing of mAbs that are specific to the cancer antigens; II) synthesis of scFv cDNA and clone into Chimeric Antigen Receptor (CAR) cassette in Lentivector (e.g. anti-BCMA scFv in 3rd generation CAR cassette in lentivector); III) packaging and production of high titer lentivirus CAR encoding lentivirus; IV) isolation, activation and expansion of patient-derived T cells that exhibit a specific cellular phenotype (e.g. CD4+ or CD8+ or a mix); V) and transduction of activated T cells with CAR-encoding lentivirus; VI) Validation of engineered CAR-T cells through FACS and functional analysis. BPS has developed an anti-BCMA CAR Jurkat/NFAT-luciferase stable reporter cell line, it is one of a series of reporter bioassays using CAR-T Lentivirus and Jurkat/NFAT-luciferase reporter cell lines. The anti-BCMA CAR Jurkat/NFAT-luciferase reporter cell line is a great system to predict the mechanism of action (MOA) and therapeutic potential of the anti-BCMA CAR lentivirus before using it with patient-derived primary T cells. It is a single cell clonal stable cell line developed by transducing the Jurkat/NFAT-Luciferase reporter cells with the anti-BCMA scFV CAR lentivirus (BPS Bioscience #79701).
Product Description
CAR-TThe anti-BCMA CAR Jurkat/NFAT-luciferase reporter cell line is a stable cell line made from the anti-BCMA scFV CAR lentivirus (BPS Bioscience #79701). It has been validated for anti BCMA-CAR expression by FACS, and for functional activation stimulated by both soluble BCMA protein (BPS Bioscience #79467) and BCMA/CHO target cells (BPS Bioscience #79500).
Product Specifications
| Host Cell Line | Jurkat (clone E6-1) |
|---|---|
| Host Species | Human t lymphoblast, suspension |
| Transfection Method | Lentivirus, BPS# 79701 |
| Supplied As | Each vial contains 2 x 10^6 cells in 1 ml of 10% DMSO and 90% FBS |
| Harmonized Tariff Code | 3002-5900 |
Quality Control & Validation
✓ Mycoplasma-TestedThe cell line has been screened using the PCR-based Venor™GeM Mycoplasma Detection kit (Sigma-Aldrich, #MP0025) to confirm the absence of Mycoplasma species.
Usage Notes
See assay protocol for detailed instructions.
Regulatory Information
License Disclosure
Related Products
Related Products: Cat. #60690, 60184, 79500, 79701, 79796, 79784
Required Accessories: Cat. #60184,79784,79796,60690
This product is engineered on a Jurkat (clone E6-1) background (Human origin). The Jurkat (clone E6-1) host was selected for its compatibility with stable transfection and the target pathway or assay type. Consult the product datasheet for passage number guidance and recommended culture media.
This product is classified as BSL-1. Standard microbiological practices (gloves, lab coat, eye protection) are sufficient. No specialized containment facility is required beyond a clean bench. Consult your institutional IBC for GMO registration requirements.
Yes. The cell line has been screened using the PCR-based Venor™GeM Mycoplasma Detection kit (Sigma-Aldrich, #MP0025) to confirm the absence of Mycoplasma species. We recommend that you independently confirm mycoplasma-negative status after receipt and periodically during routine culture using a validated detection kit.
Store this product at Liquid Nitrogen. Specifically: Immediately upon receipt, store in liquid nitrogen. Transfer cells from dry-ice shipping to the recommended storage immediately upon receipt. Avoid repeated freeze-thaw cycles, which reduce viability and may alter expression characteristics.
Yes, a license is required (Yes). Purchase of this cell line grants a time-limited research-use license for use in your immediate laboratory only. This license does not permit redistribution, sub-licensing, transfer to other institutions, or commercial use. Refer to the License Disclosure section on this page or contact BPS Bioscience for details regarding modifications or commercial licensing.
This stable cell line was generated using Lentivirus, BPS# 79701 for transgene delivery into the parental host. The stably integrated cells were selected using the appropriate resistance marker and verified for expression prior to cryopreservation.
Can't find the cell line you need—or require a custom engineered model for your study? We offer end-to-end support for diverse research needs, including:
- Cell line sourcing and selection (species, tissue, and disease model matching)
- Stable cell line engineering (overexpression, knockdown, knockout via CRISPR/Cas9, shRNA, sgRNA)
- Reporter gene integration (GFP, RFP, luciferase, fluorescent/bioluminescent constructs)
- Genome editing and knockin (point mutations, tagged endogenous proteins, conditional alleles)
- Inducible expression systems (Tet-On/Off and regulatable constructs)
- Drug resistance marker selection (puromycin, G418, hygromycin, and others)
- Custom growth and media optimisation for specific assay requirements
- Scale-up production for high-throughput screening campaigns
- Authentication and QC services (STR profiling, mycoplasma testing, viability assessment)
Click Talk to a Scientist to submit a request form, email us at support@biohippo.com, or explore our Research Services for additional support. Our team will be in contact with you shortly.
- Immune checkpoint blockade and CAR-T cell therapy in hematologic malignancies. Wang et. al. J Hematol Oncol. 2019 Jun 11;12(1):59
- Chimeric antigen receptor T cell therapy for multiple myeloma. Hasegawa et.al. Inflamm Regen. 2019 Jun 4;39:10.
- Novel targets for the treatment of relapsing multiple myeloma. Giuliani et. al. Expert Rev Hematol. 2019 Jun 3:1-16.
- Anti-BCMA antibodies in the future management of multiple myeloma. Gavriatopoulou et. al. Expert Rev Anticancer Ther. 2019 Apr;19(4):319-326.